SAFE Study is looking at the safety and effectiveness of a drug called aPCC for people with hemophilia A, a condition where the blood doesn't clot well. Some people with hemophilia A develop inhibitors, which are blockers that make treatment harder. These patients are already on a medicine named emicizumab to help prevent bleeding. The study is for those who have serious bleeding episodes or need special procedures. Participants must be at least 6 years old, have certain levels of blood components, and meet other health criteria. The study will not include anyone with other bleeding disorders, certain health conditions, or those taking specific medications.

• The study requires participants to have regular check-ups and tests.
• Participants will receive a personalized dose of aPCC based on their needs.
• Risks might include allergic reactions or other side effects.

If you think you might fit the criteria, you and your caregiver will need to provide consent to join the study. It's important to discuss with your doctor to see if this study could be beneficial for your condition.